🧬 A Personalized mRNA Cancer Vaccine Has Passed Its Biggest Test Yet

For the first time, a personalized mRNA cancer therapy has succeeded in a Phase 3 clinical trial — the final major testing stage before regulators can consider approval.

The treatment, called intismeran autogene, is not an off-the-shelf vaccine. Doctors sequence each patient’s tumour, identify mutations unique to their cancer, and manufacture an individual mRNA therapy encoding up to 34 of those tumour-specific targets. The goal is essentially to give the immune system a personalized wanted poster for the cancer.

In the trial, 1,137 people with stage IIB–IV melanoma whose tumours had been completely removed received either the personalized mRNA therapy plus the immunotherapy drug pembrolizumab (Keytruda), or pembrolizumab alone. The combination produced statistically significant and clinically meaningful improvements in both recurrence-free survival and distant-metastasis-free survival. No new safety signal was reported.

There is an important caveat: the companies have so far announced only top-line Phase 3 results. They have not yet released the detailed numbers, and it is not yet known whether the treatment ultimately extends overall survival. The therapy also remains investigational and has not been approved.

But the principle is now much harder to dismiss. Instead of finding one cancer vaccine that works for everyone, medicine may be able to manufacture a different vaccine for each individual tumour.

Cancer is personal.

The vaccine might have to be too.

#Cancer #mRNA #Melanoma #Immunotherapy #Biotechnology #Medicine #Science